Journal of Clinical Oncology, Volume 44, Issue 12, Page 1068-1071, April 2026.

Journal of Clinical Oncology, Volume 44, Issue 12, Page 1120-1129, April 2026.

Journal of Clinical Oncology, Volume 44, Issue 12, Page 1076-1082, April 2026.

Journal of Clinical Oncology, Volume 44, Issue 12, Page 1166-1173, April 2026.

Journal of Clinical Oncology, Volume 44, Issue 12, Page 1108-1119, April 2026.

Journal of Clinical Oncology, Volume 44, Issue 12, Page 1145-1165, April 2026.

Journal of Clinical Oncology, Volume 44, Issue 12, Page 1098-1107, April 2026.

Journal of Clinical Oncology, Volume 44, Issue 12, Page 1083-1097, April 2026.

Journal of Clinical Oncology, Volume 44, Issue 12, Page 1139-1144, April 2026.

Journal of Clinical Oncology, Volume 44, Issue 12, Page 1174-1174, April 2026.

Journal of Clinical Oncology, Volume 44, Issue 12, Page 1175-1177, April 2026.

Journal of Clinical Oncology, Volume 44, Issue 12, Page 1177-1178, April 2026.

Journal of Clinical Oncology, Volume 44, Issue 12, Page 1065-1067, April 2026.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

Journal of Clinical Oncology, Ahead of Print.

New England Journal of Medicine, Volume 394, Issue 16, Page 1595-1607, April 23, 2026.

New England Journal of Medicine, Volume 394, Issue 16, Page 1608-1620, April 23, 2026.

New England Journal of Medicine, Volume 394, Issue 16, Page 1583-1594, April 23, 2026.

New England Journal of Medicine, Volume 394, Issue 16, Page 1621-1633, April 23, 2026.

New England Journal of Medicine, Volume 394, Issue 16, Page 1656-1659, April 23, 2026.

New England Journal of Medicine, Volume 394, Issue 16, Page 1659-1661, April 23, 2026.

New England Journal of Medicine, Volume 394, Issue 16, Page 1647-1648, April 23, 2026.

New England Journal of Medicine, Volume 394, Issue 16, Page 1634-1634, April 23, 2026.

New England Journal of Medicine, Volume 394, Issue 16, Page 1635-1645, April 23, 2026.

New England Journal of Medicine, Volume 394, Issue 16, Page 1568-1569, April 23, 2026.

New England Journal of Medicine, Volume 394, Issue 16, Page 1566-1568, April 23, 2026.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

A 60-year-old woman with follicular lymphoma was evaluated for swelling and proteinuria that had persisted for 2 weeks. The patient’s plasma was clear at 37°C but turbid at 4°C. A kidney biopsy was performed.

Among men with locally advanced prostate cancer, transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival and led to a lower incidence of hot flashes but a higher incidence of gynecomastia.

In a placebo-controlled trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding.

In a phase 3 trial, ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag, with a stable platelet response at 6 months in a higher percentage of patients with 9 mg/kg of ianalumab than with placebo.

Combined oral contraceptives and hormone-replacement therapy increase the risk of venous thromboembolism, although the absolute risk is low. Transdermal estradiol and micronized progesterone carry lower risk.

Despite the implementation of efficacious interventions for secondary prevention, patients with ischemic stroke or transient ischemic attack (TIA) remain at substantial residual risk for short- and long-term recurrent ischemic stroke and coronary events.1,2 Approximately three quarters of ischemic strokes or TIAs are noncardioembolic and may be attributable to...

The Trump administration’s wide-ranging actions to dismantle U.S. environmental regulations will cause long-lasting health harms, disproportionately affecting low-income and other vulnerable groups.

In a patient with metastatic cervical cancer treated with the nectin-4–targeted antibody–drug conjugate bulumtatug fuvedotin, a new hepatic lesion proved to be pseudoprogression and resolved with continued therapy.

In a phase 1 trial of first-line zongertinib for HER2-mutated non–small-cell lung cancer, an objective response occurred in 76% of patients, with a median progression-free survival of 14.4 months.

The discovery that many lung cancers are driven by a single dominant constitutively activated “driver” oncogene represented a quantum leap in the therapy of lung cancer. Potent small molecules were developed that could turn off these genes, with dramatic clinical therapeutic efficacy. Before their discovery, cancer therapeutics were identified by...

Post-thrombotic syndrome is the most common chronic complication of deep-vein thrombosis (DVT), affecting 20 to 50% of patients with DVT and causing debilitating symptoms involving the limbs — including pain, swelling, skin changes, and venous ulcers — that substantially reduce quality of life and impose considerable socioeconomic burden.1 ...

Among adults with persistent or chronic ITP, the incidence of adverse events with mezagitamab appeared to be similar to that with placebo. Mezagitamab treatment appeared to result in increased platelet counts at all three doses tested.

In a phase 1 trial of setidegrasib, a KRAS G12D degrader, 42% of patients had adverse events of grade 3 or higher; 36% of patients with NSCLC and 24% of those with pancreatic cancer had a response.

A study in a mouse model of MYCN-amplified neuroblastoma implicates polyamine levels in affecting the makeup of the proteome and biologic characteristics of the tumor.

An 83-year-old woman with worsening type 2 diabetes presented with a 6-month history of painful rash. Hyperpigmented plaques with coalescing erosions and blisters were seen. Abdominal CT revealed a mass in the tail of the pancreas.

In this study, a Cas12a–guide RNA complex was used to target the promoters of HBG1 and HBG2 in autologous stem cells to treat sickle cell disease.

In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years.

In this study, a Cas12a–guide RNA complex was used to target the promoters of HBG1 and HBG2 in autologous stem cells to treat transfusion-dependent β-thalassemia.

Transfusion-dependent β-thalassemia and sickle cell disease, both characterized by defective hemoglobin synthesis, are the most common monogenic diseases worldwide. Each year, approximately 60,000 infants are born with transfusion-dependent β-thalassemia, and 500,000 infants receive a diagnosis of sickle cell disease.1,2 Historically, patients with these disorders have rarely survived beyond...

Although bladder preservation with trimodal therapy is a category 1 recommendation in the National Comprehensive Cancer Network (NCCN) guidelines for appropriately selected patients with muscle-invasive bladder cancer, the real-world adoption of this type of therapy in the United States remains disappointingly low. Contemporary data suggest that only half the patients...

A month after the USA and Israel launched attacks on Iran, Iran and the USA agreed to a conditional 2-week ceasefire on April 8, 2026. However, strikes continued in Lebanon, and after peace talks failed to come to a resolution an end to the war is no closer at the time of writing and the situation in the region remains precarious. Furthermore, the effects of the US–Israel–Iran war are being felt not only in the region, but also globally, and the impact on health care worldwide is under-appreciated and likely long-lasting.

The advent of CDK4/6 inhibitors combined with endocrine therapy has substantially transformed the treatment approach for patients with HR+/HER2– metastatic breast cancer;1 however, acquired resistance inevitably develops, making the optimal sequencing of subsequent targeted therapies a substantial challenge. Aberrant activation of the PI3K/AKT/PTEN signalling axis is frequently identified as a key contributor to CDK4/6 inhibitor cross-resistance, providing a robust biological rationale for therapeutic intervention.

Over the past decade, phase 3 trials have consistently demonstrated substantial progression-free survival and overall survival improvements with the addition of CDK4/6 inhibitors to endocrine therapy. The meta-analysis of Beshr and colleagues1 in The Lancet Oncology provides the most up-to-date analysis of data from phase 3 trials comparing CDK4/6 inhibitors plus endocrine therapy with endocrine therapy alone. By consolidating survival results, efficacy of this drug class in treatment of HR+/HER2– metastatic breast cancer is reaffirmed.

Prostate-specific antigen (PSA) was discovered in 1960 and introduced as a biomarker for prostate cancer in 1987.1 Since then, PSA has been used for screening, detecting recurrence after prostatectomy or radiotherapy, and monitoring treatment response. Early work also demonstrated that PSA concentrations measured 6–9 months after initiating castration represent a major prognostic factor in metastatic castration-sensitive prostate cancer.2

The rarity and heterogenous presentation of extremity soft tissue sarcomas complicates large-scale studies on diagnosis, disease monitoring, and outcome prediction. Histological subtype, grading, tumour size, location, resectability (with wide margins), administration of adjuvant or neoadjuvant radiotherapy, and chemotherapy all influence oncological outcomes, including local recurrence and risk of distant metastasis, as well as overall survival (figure).1 Given that the estimated prognosis of patients with soft tissue sarcoma guides decisions on individual treatment concepts, patient counselling, and follow-up strategies,2 the accurate prediction of oncological outcomes is important.

In 2019, the UN Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), whose mandate is to undertake scientific evaluations of the sources, effects, and risk of ionising radiation,1–3 convened a group of experts to review the latest epidemiological evidence on radiation and cancer risk. The updated report focuses on low-level radiation exposures; it has recently been approved and will be published in 2026.4

Cancer clinical trials are conducted by both the commercial and non-commercial sectors. Whereas clinical trials conducted by the commercial sector aim for the marketing authorisation of new drugs, the primary characteristic of independent clinical trials conducted by the academic sector is the capacity to address a wide range of clinical research questions that are generally not addressed by the drug development industry. Crucial examples include the optimisation of surgical and radiation treatments, drug dose and treatment duration, multimodality combinations, sequence of treatments, head-to-head comparison of therapeutic strategies, better identification of patients who will or will not benefit, and addressing the needs of underserved patient populations.

We congratulate Hermann Einsele and colleagues on their phase 3 CARTITUDE-4 trial, a landmark study poised to reshape the therapeutic landscape of relapsed myeloma. By finding a significant overall survival advantage with ciltacabtagene autoleucel (cilta-cel) compared with pomalidomide–bortezomib–dexamethasone or daratumumab–pomalidomide–dexamethasone in patients with lenalidomide-refractory myeloma with one to three previous lines of therapy, CARTITUDE-4 provides compelling evidence that earlier use of CAR T-cell therapy can alter disease trajectory.

We thank Jowon Laura Kim and S Vincent Rajkumar for their comments.

We read with interest the systematic review by C Tang and colleagues1 and compliment the authors for their comprehensive primary analysis of six randomised clinical trials (RCTs) comparing metastasis-directed therapy (MDT) with standard of care (SOC) in oligometastatic prostate cancer. However, we identified several important design concerns and methodological limitations that could compromise the validity and interpretation of the findings.

We thank André Vis and Kim de Vries for their interest in our WOLVERINE study.1 We agree that, optimally, there will be well conducted phase III trials to inform the benefit of metastasis-directed therapy (MDT) for oligometastatic prostate cancer. However, these trials have yet to be reported, and in the interim, clinicians are left with an increasingly common clinical scenario that requires evidence-based direction. The highest-level data available are randomised phase 2 trials. However, heterogeneity exists between these trials given inherent differences and the timeframes over which they were run.

Alger E, Regnault, A, Dueck AC, et al. A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR). Lancet Oncol 2026; 27: e218–30—The appendix of this Policy View has been corrected as of April 27, 2026.

Privé BM, Noordzij W, Muselaers CHJ, et al. [177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study. Lancet Oncol 2026; 27: 461–69—In this Article, the title has been corrected to “[177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study”. This correction has been made to the online version as of April 27, 2026.

In March, 2026, a Working Group of 12 scientists from nine countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to finalise their evaluation of the carcinogenicity of tris(chloropropyl) phosphate (TCPP), butyraldehyde, and cumyl hydroperoxide.

A US oil blockade causing several power blackouts in Cuba has led to tens of thousands of delayed surgeries while the health system tries to prioritise urgent care, including radiotherapy for 16 000 patients with cancer and chemotherapy for another 12 400 patients with cancer, say Cuban health authorities and the UN.

The US National Cancer Institute (NCI) and the Foundation for the National Institutes of Health have launched a partnership to raise nearly US$200 million to fund clinical trials for cancer vaccines, including mRNA-based approaches for patients at high risk of tumour recurrence.

19 US senators wrote to Health and Human Services Secretary Robert F Kennedy Jr on March 24, 2026, demanding he explain why the US Preventive Services Task Force (USPSTF)—the independent expert panel that has determined which cancer screenings and other preventive care Americans can access at no cost for four decades—has not met for a year. They called on Kennedy to submit an overdue, legally required annual USPSTF report to Congress, and to fill five vacancies among the 16 Task Force seats.

Canada's vast Yukon Territory in the country's northwest has published its first ever First Nations Cancer Strategy, aiming to improve cancer diagnosis, treatment, and care across the board for its First Nations people, who make up just less than 20% of the territory's population of around 48 000 people (2025 estimate). Some three-quarters of the population live in Whitehorse, the territory's capital near the southern border with the Province of British Colombia.

Preliminary results of the ADARNAT pilot phase suggest that axillary radiotherapy (ART) without lymphadenectomy might safely replace axillary lymphadenectomy (ALND) in patients with limited node disease. Amparo Garcia-Tejedor (Hospital Universitari de Bellvitge, Gynecology, Hospitalet de Llobregat, Spain) presented results from the pilot phase of ADARNAT trial, an open-label, randomised, phase 3 multicentre trial across 23 Spanish hospitals. 272 patients with breast cancer (cT1–T4b, and cN0–cN1) treated with neoadjuvant therapy and 1–2 positive sentinel lymph nodes at surgery were randomly assigned to receive ART or ALND.

A new aligned pathway has been established by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) to facilitate earlier patient access to medicines, according to recently published guidance.

Medical groups are preparing to lobby Congress over health cuts proposed in the 2027 budget by the US Trump administration in the hope that lawmakers will ensure funding when spending plans are negotiated in the coming months.

It caught my attention one Sunday as I did inpatient rounds. Pinned to a corkboard, fading slightly at the edges, the drawing looked almost childish at first glance. A smiling stick figure labelled CHEMO MAN, organs sketched in block letters and arrows pointing outwards with names of drugs and toxicities carefully written in pen. Doxorubicin for the heart. Bleomycin for the lungs. Cisplatin for the kidneys. Methotrexate for the liver. Vincristine for the nerves. A mnemonic rendered as a body and, unintentionally, a theory of learning.

On Jan 20–25, 2026, the Business Design Centre in London, UK, hosted the annual London Art Fair, which for the first time had Cancer Research UK (London, UK) as its official charity partner. Cancer Research UK, used their platform at the London Art Fair to showcase two artists whose lives have been affected by breast cancer. Tucked away in a quiet upstairs corner of the fair, slightly aside from the bustling central area, Cancer Research UK's relatively small exhibition displayed the works of Dr Helen Anahita Wilson and Carole Ellis, two revolutionary and incredibly talented artists and survivors of breast cancer.

These findings highlight the substantial and growing burden of cancers, especially in low-income and middle-income countries, where many people who develop cancer die undiagnosed. Accounting for demographic and epidemiological trends as well as health system factors, our modelling framework enables evaluation of targeted interventions to strengthen the cancer workforce and improve diagnostic pathways across diverse geographical and socioeconomic settings.

Disparities in global cancer survival are large and are expected to persist on current trends without transformative policy action. Our modelling framework provides comprehensive, country-level projections of survival and mortality for multiple cancers, accounting for demographic and epidemiological trends, as well as health system barriers and workforce constraints.

Investments to strengthen the cancer workforce will be essential to reduce global cancer mortality and improve timely diagnosis and survival. Strategic scale-up of personnel, particularly in diagnostics, alongside innovative strategies such as digital health solutions and role delegation, could result in substantial improvements in cancer outcomes. Policy makers should prioritise data-driven workforce planning as a crucial component of comprehensive cancer control strategies.

The combination of fulvestrant, ipatasertib, and palbociclib showed preliminary signs of clinical activity and showed expected adverse events in heavily pretreated patients with HR+/HER2– metastatic breast cancer, warranting further evaluation in those with CDK4/6 inhibitor-refractory disease.

CDK4/6 inhibitors plus endocrine therapy significantly improved survival in hormone receptor-positive, HER2-negative advanced breast cancer. Benefits in progression-free survival and overall survival were consistent across major clinical subgroups. Although all agents improved progression-free survival, only ribociclib and abemaciclib showed statistically significant overall survival benefits, whereas palbociclib did not, and data for dalpiciclib remain immature. Further head-to-head comparisons and assessments of toxicity profiles, as well as patient-reported outcomes, are needed.

Performing SLNB or cALND solely to determine eligibility for CDK4/6 inhibition requires very high number needed to diagnose and treat, adds substantial morbidity, and is costly, with only marginal overall survival benefit.

Along with the known survival benefits, the clinically meaningful delays in pain progression and time to deterioration of overall wellbeing support consideration of darolutamide plus ADT as a standard-of-care treatment option in patients with mHSPC.

Metastatic volume or nodal status influence survival rates associated with on-treatment serum PSA categories, including for undetectable PSA. Radiological features and serum PSA could be combined to better predict survival. PSA at 24 weeks showed strongest associations with overall survival, although a PSA concentration of 0·2 ng/mL or less at any timepoint predicted favourable outcome. These findings could inform prognosis and warrant evaluation for treatment selection in clinical trials.

BayeSarc is a continuously updatable, accurate, and precise prognostic tool for soft tissue sarcomas in the extremities. It reduces uncertainty, adapts to temporal changes, and refines variable weights. Its incorporation into the Sarculator app enables immediate clinical use, with potential to improve patient counselling, guide treatment decisions, and refine trial design. More broadly, the BSL framework provides an innovative and generalisable approach to prognostication in rare cancers, moving beyond the traditional two-step development–validation paradigm, enabling more efficient use of patient data.

Oligometastatic cancer is characterised by a low volume of metastases to a small number of anatomical sites. However, evaluating the impact of metastases-directed therapies (MDTs) on overall survival or quality of life is often challenging. Current clinical trials use a wide range of primary endpoints that might not be validated or suited to MDT. To address this issue, we did a systematic review of international trial registries, alongside a Delphi consensus process involving 30 experts and five patient representatives.

This multisociety, multidisciplinary consensus—formally endorsed by the European Society of Surgical Oncology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology—was developed to standardise the assessment of ablation margins in liver tumour thermal ablation. A modified Delphi process, consisting of two online surveys and a hybrid (online and in-person meeting in Innsbruk) consensus meeting of 72 experts from North America, South America, Europe, and Asia.

Thermal ablation offers a safer, less invasive, and more cost-effective curative-intent treatment for selected patients with primary and metastatic liver tumours than surgery; when done with appropriate technique, ablation can deliver similar oncological outcomes. However, effectiveness in routine practice varies because structured training, planning, and procedural governance remain scarce. These international multidisciplinary, multi-society guidelines—formally endorsed by the European Society of Surgical Oncology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology—define key domains contributing to procedural difficulty and practice variation in liver tumour thermal ablation.

This cohort study investigates the association of the COVID-19 pandemic with short-term survival among patients diagnosed with cancer in 2020 and 2021 using US population-based cancer registry data.

This cohort study compares cancer control and perioperative complications among patients after salvage focal therapy vs salvage radical prostatectomy.

This secondary analysis examines 15-year follow-up data from a randomized clinical trial to evaluate the potential for long-term remission and cure for follicular lymphoma following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin/doxorubicin, oncovin, and prednisone/prednisolone (CHOP)–based regimens.

This cohort study evaluated the performance and generalizability of 2 open-source artifical intelligence models in predicting mutations in

This cohort study evaluates the association between adjuvant imatinib and recurrence-free survival and overall survival in patients with resected high-risk gastrointestinal stromal tumors (GISTs) with

This secondary analysis of the GHSG HD21 randomized clinical trial evaluates the tolerability and impact of BrECADD vs escalated BEACOPP on health-related quality of life for patients with Hodgkin lymphoma.

This cohort study examines cardiovascular disease risk, incidence, and mortality among adolescents and young adults with cervical high-grade squamous intraepithelial lesions (HSILs).

This cohort study examines the association of bruton tyrosine kinase inhibitor therapy in B-cell malignant disease with increased risk of pericardial effusion and cardiovascular outcomes.

A 67-year-old man with a history of λ light-chain multiple myeloma presents with increased serum-free λ light chain levels. What is your diagnosis?

This Viewpoint discusses improving US cancer surveillance systems to address veteran-specific risks and outcomes.

This Viewpoint discusses advances in cancer vaccines, including the use of COVID-19 pandemic–related infrastructure, clinical trial results, and harnessing artificial intelligence.

This Viewpoint examines the challenges and strategies for improving public health literacy related to cancer research and care, including effective communication and ethical engagement among researchers, health care professionals, and patients.

This

This essay describes a turn of events that compelled a medical oncology fellow to learn to care for young patients with sarcoma and to rediscover why he chose medicine in the first place.

Up to three-quarters of people with haemophilia worldwide are estimated to be undiagnosed, with an even bigger gap predicted for other bleeding disorders. This astonishing statistic underlies the focus of this year's World Haemophilia Day, on April 17, on diagnosis: a first step to care. Even when people are diagnosed, there are substantial inequalities in access to treatment and bleeding prophylaxis in many parts of the world. 2026 could mark a crucial year for turning the tide on these issues, with the recent approval of a World Health Assembly (WHA) resolution on Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders, which will be presented at the 79th WHA on May 18–23, 2026, for final adoption.

In 2024, WHO updated haemoglobin thresholds and revised the adjustments for altitude and smoking.1 The earlier elevation adjustments were established in 1989 and were based on a demographically limited subset of populations and did not adequately represent the diversity of global populations. The 2024 updated elevation adjustment was based on the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project, which leverages multinational surveys with broader geographical and demographic representation than previous methods.

In The Lancet Haematology, Dominik Dytfeld and colleagues1 report the findings from the phase 3 ATLAS trial, comparing carfilzomib–lenalidomide–dexamethasone with lenalidomide alone as maintenance therapy after autologous haematopoietic stem-cell transplantation (HSCT) in patients with newly diagnosed multiple myeloma. Lenalidomide monotherapy has long been the global standard of care in this setting, based on consistent improvements in progression-free survival and overall survival.2 With a median follow-up of nearly 6 years, carfilzomib–lenalidomide–dexamethasone maintenance significantly improved 4-year progression-free survival (67·5% [95% CI 56·2–76·4] vs 38·0% [27·6–48·2]; hazard ratio 0·46 [95% CI 0·30–0·70]) with a manageable safety profile.

The RESMAIN trial by Rudolf Stadler and colleagues, published in The Lancet Haematology, showed that resminostat maintenance therapy significantly prolonged median progression-free survival (median 8·3 months, 95% CI 4·2–15·7) compared with placebo (4·2 months, 2·8–6·4) in patients with advanced-stage mycosis fungoides or Sézary syndrome.1 These diseases are characterised by repeated cycles of remission and relapse. Therefore, progression-free survival does not carry the same clinical implications as in acute leukaemia or solid tumours, in which relapse is often associated with worse survival.

I would like to thank Takashi Miyachi and colleagues for their Correspondence regarding the RESMAIN trial. The most prevalent forms of cutaneous T-cell lymphoma are mycosis fungoides and its variants, as well as Sézary syndrome. According to the current guidelines, in the early stages of the disease, the recommended therapeutic approach is based on skin-directed therapies. In more advanced stages of the disease, the recommended treatment involves primarily non-toxic systemic drugs, such as pegylated interferon, bexarotene, and combinations with radiotherapy or extracorporeal photopheresis.

Olíva EN, Cottone F, Unni S, et al. Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial. Lancet Haematol 2026; 13: e169–80—In figure 2 of this Article, the two groups were incorrectly labelled “Q+stdCT” and “Q+stdCT” instead of “Q+stdCT” and “P+stdCT”. This correction has been made as of April 2, 2026.

Perrot A, Frenzel L. Maintenance intensification after autologous HSCT: refining selection. Lancet Haematol 2026; published online March 11. https://doi.org/10.1016/S2352-3026(26)00064-5—In this Comment, the title should have been Maintenance intensification after autologous HSCT: refining selection. This correction has been made as of March 19, 2026.

Dytfeld D, Wróbel T, Jamroziak K, et al. Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial. Lancet Haematol 2026; 13: e241–53—Anna Puła's affiliations should have been “Medical University of Lodz, Lodz, Poland” and “University of Chicago, Chicago, IL, USA”. Agnieszka Druzd-Sitek's and Prof Jan Walewski's affiliation should have been “Maria Skłodowska-Curie National Research Institute of Oncology, ERN EuroBloodNet, Warsaw”.

WHO has adopted a resolution to advance health equity for people with haemophilia and other bleeding disorders. Led by Armenia and co-sponsored by 12 countries across Europe, Asia, Africa, and the Americas, the resolution was approved by the WHO Executive Board (EB158) meeting on Feb 3, 2026, and aims to improve access to care and treatment worldwide. Armen Melkonyan, Head of International Relations at the Ministry of Health in Armenia, presented the resolution, which seeks to establish an international framework to improve care and treatment for people with haemophilia and other bleeding disorders.

Jayastu Senapati and Naval G Daver

I write on a day of unexpected personal and professional convergence. This past week, I spent long days in strategic discussions on enabling cell and gene therapy programmes—expanding access to advanced therapeutics and building infrastructure so that patients in our region might benefit from innovation at home rather than waiting for it to become available elsewhere. The work was forward-looking and ambitious. Yet I awoke today to news and sounds of interception explosions that, for the first time, felt unexpectedly and uncomfortably close to my new home, the United Arab Emirates.

Deucrictibant significantly reduced the severity of hereditary angioedema attacks compared with placebo; these results support continued investigation of antagonism of the bradykinin B2 receptor with an orally available agent as a potentially effective approach, with a safety profile similar to placebo, for on-demand treatment.

To the best of our knowledge, this trial provides the first clinical evidence and proof-of-concept for bradykinin B2 receptor antagonism as a therapeutic approach for the prevention of hereditary angioedema attacks and supports further investigation of oral deucrictibant for bradykinin-mediated angioedema.

Understanding the effect of anaemia requires unbiased and comparable estimates of anaemia burden. To our knowledge, we produced the first set of global estimates of anaemia burden by location, year, age, and sex using the WHO 2024 elevation adjustment method and compared them with estimates using the previous method. Policy makers should consider this modification when designing interventions to manage and prevent anaemia, particularly in regions most affected by changes in elevation adjustment.

The enhanced efficacy of carfilzomib–lenalidomide–dexamethasone treatment following autologous HSCT in patients with newly diagnosed multiple myeloma, assessed within a framework of de-escalation based on MRD status and individual risk, supports strategies for maintenance therapy intensification in this setting.

Haemophilia care has progressed through successive therapeutic revolutions, from plasma-derived and recombinant factor replacement to extended half-life products and non-factor therapies. The introduction of gene therapy, with currently approved approaches using adeno-associated viral vectors to deliver functional copies of the factor VIII or IX gene into hepatocytes, now represents the next paradigm shift: a one-time, irreversible intervention designed to restore endogenous factor production. Although early results are promising, the experience of transfusion transmitted infections reminds the haemophilia community that innovation must be matched by vigilance, transparency, and accountability.

Rebalancing agents represent a novel therapeutic class in haemophilia, designed to restore the deficient thrombin generation that underlies bleeding. Unlike factor replacement or factor VIII mimetic therapies, rebalancing agents act by downregulating natural anticoagulants. By partially inhibiting these physiological brakes of coagulation, they induce a controlled and reversible procoagulant shift. These agents have shown clinically meaningful reductions in bleeding rates across both haemophilia A and B, including in patients with inhibitors.

With the increasing adoption of posttransplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis, survival outcomes after HLA-mismatched donor hematopoietic cell transplantation are now comparable to those achieved with HLA-matched donors. Shaffer, Lee, and Perales review how this paradigm shift influences donor selection decisions and provide illustrative case vignettes highlighting concepts applicable to different clinical scenarios.

VCAR33 is a donor-derived anti-CD33 chimeric antigen receptor-modified (CAR) T-cell developed for relapsed acute myeloid leukemia (AML) following allogeneic hematopoietic cell transplantation. Mushtaq et al report a phase 1/2 study of 15 adults with relapsed or measurable residual disease–positive AML or myelodysplastic syndrome with a generally manageable toxicity profile of mostly low-grade cytokine release syndrome, limited neurotoxicity, and one case of grade III graft-versus-host disease. There is a 20% response rate and evidence of in vivo expansion, supporting early anti-leukemic activity.

There is a critical need for targeted approaches to eliminate ABO-responsive B cells to enable ABO-incompatible solid organ transplantation. While anti-CD20 therapies such as rituximab are effective, they cause broad B-cell depletion and increase infection risk. Choi et al describe a T-cell–recruiting bispecific antibody–ligand conjugate that selectively eliminates blood group–responsive B cells, demonstrating depletion of A antigen–specific B cells in human peripheral blood mononuclear cells with efficacy comparable to rituximab while sparing bystander B cells, supporting further development toward human translation.

Oncogenic mutations in SF3B1 are among the most common lesions in myeloid malignancies and chronic lymphocytic leukemia, classically linked to aberrant splicing of protein-coding sequences. Sekrecki et al uncovered a previously unrecognized function, showing that mutant SF3B1 rewires noncoding mRNA splicing to drive malignant phenotypes while creating therapeutic vulnerabilities. Specifically, missplicing of DCAF16 increases its protein expression, suggesting the potential to exploit BRD4-targeting protein degraders in SF3B1-mutant disease. This work reframes SF3B1 biology by demonstrating that altered splicing of untranslated regions can promote gain-of-function effects and reveal new treatment strategies.

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy comprising multiple biologically distinct subgroups. Ranasinghe et al identified a new genome-wide significant risk locus for pan-AML, along with 3 additional loci associated with specific subgroups, including AML with chromosome 5 and/or 7 deletions and cytogenetically complex disease. They also show that variants linked to clonal hematopoiesis risk are similarly associated with AML. These findings refine our understanding of AML etiology and highlight shared genetic susceptibility with clonal hematopoiesis.

ANKRD26-related thrombocytopenia 2 (THC2) is a rare inherited platelet disorder caused by germline variants in the 5′ untranslated region of ANKRD26. Chen et al investigated defective megakaryopoiesis in THC2 by using single-cell transcriptomics and ex vivo functional profiling of bone marrow samples from 4 affected patients. They identified reproducible abnormalities in progenitor expansion and increased apoptosis of polyploid megakaryocytes, and they propose a novel mechanism in which centrosomal overexpression of ANKRD26 drives polyploid megakaryocyte apoptosis through JUNB-mediated induction of p21 transcription.

With increasing frontline use of blinatumomab for acute lymphoblastic leukemia (ALL), its impact on subsequent CD19 chimeric antigen receptor (CAR) T-cell therapy outcomes is a key clinical question. Srinagesh et al leveraged data collected by the Real-World Outcomes Collaborative of CAR-T in Adult ALL consortium for 271 adults, and they report that prior nonresponse to blinatumomab was associated with inferior survival after brexucabtagene in comparison to blinatumomab-naïve patients (12-month progression-free survival, 33% vs 60%; overall survival, 51% vs 72%). Notably, early CAR-T responses were uniformly high (∼90% complete remissions with or without hematologic recovery at day 28) regardless of prior exposure or response. These data highlight that resistance to blinatumomab may identify patients at higher risk of post–CAR T relapse despite excellent initial responses.

Fianlimab plus cemiplimab demonstrated modest clinical efficacy with an acceptable safety profile in patients with advanced malignancies across several tumor types mostly in treatment‐naive patients. Further investigation is warranted.

Tonsillar cancers carried the highest DALY burden among HPV‐associated OPCs in US men. Patients who were aged 65 years and older and were never vaccine‐eligible presented significant DALY increases across all cancer subsites, emphasizing the need for gender‐neutral HPV vaccination and catch‐up programs for high‐risk older men.

The treatment landscape for advanced pancreatic cancer is shifting. The common RAS mutation is now targetable and the race for the most effective inhibitor is heating up.

Dietary patterns in young patients with lung cancer suggest that many have higher dietary quality scores than average U.S. reference values, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5039). The researchers...

New guidance from the American College of Physicians (ACP) says all average-risk females between ages 50 to 74 should receive biennial screening mammography for breast cancer, and that females between the ages of 40 and 49 should discuss with their doctor their risk for breast cancer and the...

Rising colorectal cancer death rates among young adults are largely concentrated among those with lower educational attainment, according to a nationwide cross-sectional analysis published in JAMA Oncology. As a result, Jemal et al reported that the disparity in mortality between individuals with...

In a cohort study reported in JAMA Oncology, Park et al found that clonal hematopoiesis of indeterminate potential (CHIP) was associated with an increased risk of trastuzumab-related cardiotoxicity in patients with breast cancer.

Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard 2 years, according to results from a phase II clinical trial presented at the American...

New data from the American Medical Association (AMA) show physician burnout continuing to decline nationwide, but significant differences across medical specialties underscore the need for more targeted solutions within health systems.

The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant consolidation of studies to only high trial volume sites in the country, according to the results of a...

As reported in The Lancet by Lorusso et al, the phase III ROSELLA trial has shown an improvement in overall survival with the addition of relacorilant to nab-paclitaxel in patients with platinum-resistant ovarian cancer. Relacorilant is a selective glucocorticoid receptor antagonist that acts to...

In a Chinese phase II trial (EC-CRT-002) reported in the Journal of Clinical Oncology, Chen et al found that the addition of the anti–PD-1 monoclonal antibody tislelizumab without maintenance cycles to induction chemotherapy and concurrent chemoradiotherapy significantly improved progression-free...

In a French phase II study (IMHOTEP) reported in the Journal of Clinical Oncology, de la Fouchardière et al found that perioperative pembrolizumab was active in previously untreated resectable localized colorectal cancer with mismatch repair deficiency (dMMR)/microsatellite instability (MSI).

Researchers at The University of Texas MD Anderson Cancer Center have identified CD40 overexpression as a potential prognostic biomarker in angioimmunoblastic T-cell lymphoma (AITL), a rare subtype of non-Hodgkin lymphoma that is difficult to diagnose and treat. The results of their study were...

A population of patients with highly refractory follicular lymphoma achieved long-standing responses with few significant adverse events from odronextamab monotherapy, according to findings of the ELM-2 study. The study outcomes were published by Tessoulin et al in Clinical Lymphoma, Myeloma &...

In a Chinese phase II study (ABC) reported in the Journal of Clinical Oncology, Li et al found that the combination of the PD-L1 inhibitor adebrelimab, bevacizumab, and cisplatin or carboplatin showed high intracranial activity and progression-free survival in patients with triple-negative breast...

In a systematic review and meta-analysis reported in JAMA Oncology, Agrotis et al found that pretreatment MRI provided important prognostic information after radical prostatectomy in patients with prostate cancer.

Early-onset of immune checkpoint inhibitor (ICI)–related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5212). The researchers suggested...

In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell lung cancer (NSCLC).

Exposure to wildfire smoke was associated with a significantly increased risk of lung, colorectal, breast, bladder, and blood cancers, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 6252).

Injecting the PD-1 inhibitor nivolumab directly into precancerous oral lesions led to reduction in lesion size and allowed some patients to avoid surgery, according to research from a phase I clinical trial (ClinicalTrials.gov identifier NCT05327270) presented at the American Association for Cancer ...

A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non–small cell lung cancer (NSCLC), according to a study presented at the American Association for Cancer Research (AACR) Annual ...

A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel led to a 100% measurable residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the...

An artificial intelligence (AI) model using DNA methylation patterns was able to classify tumors of unknown origin with high accuracy, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 3869). 

Initial data from the phase I study of WEE1 inhibitor zedoresertib and PKMYT1 inhibitor lunresertib demonstrated an expected and manageable safety profile in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A gene alterations, according to findings from the MYTHIC trial...

Elisrasib, a next-generation KRAS G12C inhibitor, demonstrated disease control in a majority of patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), whether exposed to a prior KRAS G12C inhibitor or not, according to findings from an ongoing phase I/II clinical trial presented at the ...

As reported in JAMA Oncology by Richardson et al, a secondary analysis of the GAP70+ trial showed that treatment modifications and outcomes did not differ between older patients with advanced cancer who prioritized quality of life (QOL) vs those who preferred prolonging survival.

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were previously treated with chemotherapy and immunotherapy, according to preliminary findings from an...

Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known.

A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort.

All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators.

In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock.

Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP.

The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system.

NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs.

Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source.

A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care.

To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care.

Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success.

Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC).

Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery.

In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU.

Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening.

Long considered undruggable, hypoxia-inducible factor 2α (HIF2α) has now been validated as a therapeutic target in several cancers. This Review discusses the structural basis for HIF2α druggability, the clinical results to date and key challenges, including toxicities and the need for predictive biomarkers, as well as emerging targeting modalities and combination strategies that might enhance efficacy, overcome resistance and broaden indications for HIF2 inhibition.

The ATOMIC trial has been widely celebrated as providing a positive result. However, when viewed with a lens of critical appraisal that considers issues related to overtreatment, treatment de-escalation, surrogacy, post-trial access to treatment and contributions of component, we argue that ATOMIC should not change clinical practice but rather form the basis for future trials that test de-escalation strategies.

Two recent phase II trials, INDIBLADE and SURE-02, challenge the long-standing paradigm of mandatory radical local therapy for muscle-invasive bladder cancer (MIBC). As increasingly potent systemic induction treatment strategies emerge, a key question arises: can induction therapy response guide omission of radical surgery and radiotherapy to enable preservation of an intact, functioning bladder in selected patients?

The burden of cancer therapy on patients’ time is often overlooked. Building on the ‘time toxicity’ literature, we introduce the concept of time budgeting, viewing patients’ time as a limited, measurable resource that can be managed through treatment selection, pathway design and trial protocols. We discuss the rationale, measurement challenges and implementation requirements to operationalize time budgeting in cancer care.

OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC

Rare lymphoproliferative and lymphomatous disorders occurring after chimeric antigen receptor (CAR) T cell therapy are garnering increased attention but remain incompletely characterized, complicating early recognition and management. This Review describes the spectrum of post-CAR T cell therapy lymphoproliferations reported so far, highlighting recurrent pathological and molecular features as well as factors implicated in promoting clonal expansion and/or malignant transformation, which might provide a framework to improve the diagnosis and management of these disorders.

Myelodysplastic neoplasms (MDS) comprise a heterogeneous group of malignancies that can lead to ineffective haematopoiesis, cytopenias and, potentially, progression to acute myeloid leukaemia. In this Review, the authors describe the epidemiology of MDS, which appears to be rising, as well as advances in diagnosis, risk stratification and clinical management.

Patients with meningioma, the most common type of intracranial primary tumour, have been traditionally managed with surgery and radiotherapy, although advances over the past decade have brought about promising novel treatment options. In addition, new molecularly driven classification tools can improve prognostic accuracy and guide personalized management decisions. The authors of this Review provide an integrated roadmap for meningioma care as well as a framework for ongoing and future research in this field.

Annals of Internal Medicine, Volume 179, Issue 4, Page 469-477, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 478-485, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 486-496, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 497-505, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 506-514, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 515-523, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 524-534, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 535-547, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 548-555, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 559-563, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 564-573, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 574-585, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 556-558, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 586-595, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 596-597, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 598-599, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 600-601, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 602-603, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 604-605, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 606-607, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 608-609, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 610-611, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 612, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 614-617, April 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 4, Page 617-619, April 2026. <br/>

While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.

With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.

An investigational cocktail was tied to a 0% overall response rate in patients with gastroesophageal cancer, but developers Agenus and MiNK Therapeutics aren’t giving up on the program just yet.

While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 readout in non-small cell lung cancer still leaves analysts with some questions moving into later-stage development.

Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.

Darovasertib, in combination with crizotinib, more than doubled progression-free survival in a registrational trial, leading Truist analysts to declare a “best-in-class efficacy profile” for the PKC inhibitor.

Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.”

PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect gene splicing, but the biotech attributed the poor result to an outlier.

While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.

William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s immunology and inflammation pipeline.

A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.

The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in lung cancer.

Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said on Monday. Novo plans to seek FDA approval in the back half of 2026.

In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. The Phase 3 results will support global regulatory filings.

Darovasertib, in combination with crizotinib, more than doubled progression-free survival in a registrational trial, leading Truist analysts to declare a “best-in-class efficacy profile” for the PKC inhibitor.

Sales of Amgen’s thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025.

Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of next-generation skin drugs but also shed light on how they might fare on the market.

Despite hitting its primary endpoint, Viridian’s thyroid eye disease antibody failed to ease eye bulging to the degree that analysts had been hoping for, and the biotech’s stock price fell by one-third.

Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner’s National Priority Voucher.

Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval for Xpovio in myelofibrosis, according to Jefferies analysts.

As technology becomes more integrated and personalized, experts say the biggest opportunity in diabetes management is reducing everyday burdens.

With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.

A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses at head and neck cancer.

The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in lung cancer.

An investigational cocktail was tied to a 0% overall response rate in patients with gastroesophageal cancer, but developers Agenus and MiNK Therapeutics aren’t giving up on the program just yet.

Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said on Monday. Novo plans to seek FDA approval in the back half of 2026.

While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 readout in non-small cell lung cancer still leaves analysts with some questions moving into later-stage development.

In this episode of Denatured, you’ll be hearing from Edoardo Negroni, co-founder & managing partner at AurorA-TT and Naveed Siddiqi, senior partner, Venture Investments at Novo Holdings. We debate whether Europe’s world-class science can be matched by a truly integrated venture ecosystem—and what it would take, in practice, to get there.

Despite exceptional regional hubs and research strength, investors say Europe still needs more integrated incubators, smarter regulation and broader pools of patient capital to keep breakthrough companies growing at home.

On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).

On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. 

On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024. 

On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.

On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.

On December 17, 2025, the Food and Drug Administration approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx).

On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.

On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.

On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy

On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

On November 25, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin.

On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated approval for this indication in 2024.

On November 19, 2025, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.

On November 19, 2025, the Food and Drug Administration granted traditional approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech Inc.) with bortezomib, cyclophosphamide, and dexamethasone (VCd) for newly diagnosed light chain (AL) amyloidosis. FDA granted accelerated approval for this indication in 2021.

On November 19, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.

On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (FL). The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory FL after two or more lines of systemic therapy (epcoritamab-bysp was granted accelerated approval for this indication in 2024). 

On November 13, 2025, the Food and Drug Administration approved Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) as an interchangeable biosimilar to Perjeta (pertuzumab, Genentech Inc.). This is the first approval of a biosimilar for Perjeta.

On November 13, 2025, the Food and Drug Administration approved ziftomenib (Komzifti, Kura Oncology, Inc.), a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options.

Clin Transl Med. 2021 Feb;11(2):e336. doi: 10.1002/ctm2.336.
Genç B, Gautam M, Gözütok Ö, Dervishi I, Sanchez S, Goshu GM, Koçak N, Xie E, Silverman RB, Özdinler PH

BMC Med. 2023 Nov 23;21(1):461. doi: 10.1186/s12916-023-03180-3.
Chen WJ, Gan CX, Cai YW, Liu YY, Xiao PL, Zou LL, Xiong QS, Qin F, Tao XX, Li R, Du HA, Liu ZZ, Yin YH, Ling ZY

J Clin Neuromuscul Dis. 2025 Mar 1;26(3):117-119. doi: 10.1097/CND.0000000000000517.
Hamad AA

Eur Radiol. 2020 Dec;30(12):6554-6560. doi: 10.1007/s00330-020-07034-x. Epub 2020 Jul 3.
Kalra MK, Homayounieh F, Arru C, Holmberg O, Vassileva J

Biosci Biotechnol Biochem. 2000 Dec;64(12):2734-8. doi: 10.1271/bbb.64.2734.
Kimura T, Suzuki H, Furuhashi H, Aburatani T, Morimoto K, Karita S, Sakka K, Ohmiya K

J Affect Disord. 2026 Apr 13;407:121800. doi: 10.1016/j.jad.2026.121800.
Cui Y, Sun Y, Liu S, Song J, Wang X, Li N

Demography. 2020 Feb;57(1):147-169. doi: 10.1007/s13524-019-00847-6.
Kolk M, Andersson G

Science. 2026 Apr 16:eaed1656. doi: 10.1126/science.aed1656.
Deng P, Lee H, Armijo C, Wang H, Gao A

Proc Biol Sci. 2006 Feb 7;273(1584):333-9. doi: 10.1098/rspb.2005.3311.
Gray PB, Yang CF, Pope HG Jr

Environ Sci Technol. 2025 Oct 14;59(40):21579-21588. doi: 10.1021/acs.est.5c03787. Epub 2025 Sep 8.
Bianco A, Nibert P, Wu Y, Baray JL, Brigante M, Mailhot G, Deguillaume L, Vione D, Cabanes DJE, Méjean M, Besse-Hoggan P

J Low Genit Tract Dis. 2017 Jul;21(3):198-203. doi: 10.1097/LGT.0000000000000308.
Lykkebo AW, Drue HC, Lam JUH, Guldberg R

Ophthalmol Retina. 2024 Oct;8(10):943-952. doi: 10.1016/j.oret.2024.05.003. Epub 2024 May 11.
Barkmeier AJ, Herrin J, Swarna KS, Deng Y, Polley EC, Umpierrez GE, Galindo RJ, Ross JS, Mickelson MM, McCoy RG

BMC Anesthesiol. 2026 Jan 5;26(1):70. doi: 10.1186/s12871-025-03579-w.
Wessels J, Pawlik RJ, Foerster C, Erlenwein J, Benson S, Sondermann W, Elsenbruch S, Aulenkamp J

Chest. 2007 Sep;132(3 Suppl):20S-22S. doi: 10.1378/chest.07-1345.
Alberts WM; American College of Chest Physicians

N Engl J Med. 2026 Apr 16;394(15):1467-1479. doi: 10.1056/NEJMoa2513880.
Sharma M, Dong Q, Hirano T, Kasner SE, Saver JL, Masjuan J, Demchuk AM, Cordonnier C, Bereczki D, Tsivgoulis G, Veltkamp R, Staikov I, Bae HJ, Campbell BCV, Zini A, Lee IH, Kovar M, Mikulik R, Lemmens R, Ferro JM, Robinson T, Christensen H, Ozturk S, Leker RR, Turcani P, Slowik A, Amaya P, Hoo FK, De Marchis GM, Knoflach M, Sylaja PN, Putaala J, Coutinho JM, van der Worp HB, Miglane E, Matijošaitis V, Lindgren AG, Sampaio Silva G, Sandset EC, Turuspekova ST, Amarenco P, Sheth KN, Smith EE, Eikelboom JW, Joundi RA, Schulze K, Xu L, Heenan L, Colorado P, Keller L, Muehlhofer E, Neumann C, Mundl H, Shoamanesh A; OCEANIC-STROKE Investigators

Clin Neurophysiol. 2025 Nov;179:2111005. doi: 10.1016/j.clinph.2025.2111005. Epub 2025 Sep 15.
von Quednow E, Husain N, Łajczak P, Linha Secco G, Koppanatham A

Soc Sci Med. 2009 Sep;69(5):777-85. doi: 10.1016/j.socscimed.2009.06.029.
Burgard SA, Brand JE, House JS

Proc Biol Sci. 2012 Apr 7;279(1732):1430-6. doi: 10.1098/rspb.2011.1647. Epub 2011 Oct 12.
Roberts SC, Klapilová K, Little AC, Burriss RP, Jones BC, DeBruine LM, Petrie M, Havlícek J

Am J Psychiatry. 2005 Jul;162(7):1373-5. doi: 10.1176/appi.ajp.162.7.1373.
Magnusson PK, Gunnell D, Tynelius P, Davey Smith G, Rasmussen F

Cell. 2026 Apr 16;189(8):2322-2356. doi: 10.1016/j.cell.2026.03.024.
Conrad M, Strasser A, Jost PJ, Yuan J, Shao F, Vandenabeele P, Wahida A